Sign in

    Chung Yu

    Managing Director and Senior Research Analyst at Ladenburg Thalmann

    Chung Yu is a Managing Director and Senior Research Analyst at Ladenburg Thalmann, specializing in healthcare sector equities with a particular focus on biotech and life sciences companies. He has provided coverage for firms such as OPKO Health and other industry leaders, and is recognized for a high level of analytical detail in his reports, though specific rankings or performance metrics such as TipRanks success rate are not publicly listed. With more than a decade of experience in equity research, Chung Yu began his analyst career in the early 2000s and has been with Ladenburg Thalmann for several years, following prior experience at other financial institutions. He holds professional credentials including FINRA registrations and securities licenses, supporting his role as a licensed analyst and investment professional.

    Chung Yu's questions to Evaxion (EVAX) leadership

    Chung Yu's questions to Evaxion (EVAX) leadership • Q2 2024

    Question

    On behalf of Chung Yu from Ladenburg Thalmann, an associate asked for specifics on the upcoming ESMO data for EVX-01, its potential impact on partnerships, the status of the EVX-B3 collaboration with MSD, and details about the new EDEN 5.0 AI model.

    Answer

    CSO Birgitte Rono confirmed the ESMO presentation will include a 1-year clinical readout and biomarker analysis. CEO Christian Kanstrup affirmed that positive data would be very important for advancing partnership talks. Rono and Kanstrup also noted the EVX-B3 collaboration with MSD is on track to conclude its first phase in H2 2024. Kanstrup detailed that the upgraded EDEN 5.0 model features enhanced predictive capabilities and will be applied to future internal and partnered programs.

    Ask Fintool Equity Research AI